Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas

Journal of Neuro-Oncology

Volumn 45, Issue 2, 1999, Pages 141-157

  Quattrocchi, Keith B ^a,c   Miller, Claramae H ^b   Cush, Sharon ^a   Bernard, Stephan A ^a   Dull, Scott T ^a   Smith, Michelle ^a   Gudeman, Steven ^a   Varia, Mahesh A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c St Mary's Regional Med Center   (United States)

Author keywords

Immunotherapy; Malignant gliomas; Tumor infiltrating lymphocytes

Indexed keywords

CARMUSTINE; CISPLATIN; INTERLEUKIN 2 RECEPTOR; LOMUSTINE; PROCARBAZINE; RECOMBINANT INTERLEUKIN 2; VINCRISTINE;

ADULT; ARTICLE; ASTROCYTOMA; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG CYTOTOXICITY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HELPER CELL; HUMAN; HUMAN TISSUE; MULTIMODALITY CANCER THERAPY; PILOT STUDY; RISK ASSESSMENT; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; BRAIN NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GLIOMA; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; LYMPHOCYTE TRANSFUSION; LYMPHOCYTES, TUMOR-INFILTRATING; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RECURRENCE; TRANSPLANTATION, AUTOLOGOUS;

EID: 0033506158     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006293606710     Document Type: Article

References (40)

1. Ahmad I, Longenecker M, Samuel J, Allen TM: Antibody-targeted delivery of doxorubicin entrapped in sterily stabilized liposomes can eradicate lung cancer in mice. Cancer Res 53: 1484-1588, 1993
2. Akbasak A, Oldfield EH, Saris SC: Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro. J Neurosurg 75: 922-929, 1991
3. Apuzzo MLJ, Mitchell MS: Immunological aspects of intrinsic glial tumors. J Neurosurg 55: 1-18, 1981
4. Arnold DL, Shoubridge EA, Villemure JG, Feindel W: Proton and phosporous magnetic resonance spectroscopy of human astrocytomas in vivo: preliminary observations on tumor grading, NMR Biomed 3: 184-189, 1990
5. Barba D, Saris SC, Holder CC, Rosenberg SA, Oldfield EH: Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70: 175-180, 1989
6. Black PM: Brain tumors: Part 1. NEJM 324: 1555-1564, 1990
7. Boon T: Towards a genetic analysis of tumor rejection antigens. Adv Cancer Research 58: 179-210, 1992
8. Boring CC, Squires TS, Tong T: Cancer statistics, 1993. CA Cancer J Clin 43: 7-26, 1993
9. Brooks WH, Marksbery WR, Gupta GD et al.: Relationship of lymphocyte invasion and survival of brain tumor patients. Ann Neurol 4: 219-224, 1978
10. Chen S-H, Shine DH, Goodman CJ et al.: Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci 91: 3054-3057, 1994
11. Dan MD, Schlachta CM, Guy J et al.: Human antiglioma monoclonal antibodies from patients with astrocytic tumors. J Neurosurg 76: 660-669, 1992
12. Dick SJ, Macchi B, Papazoglou S et al.: Lymphoid cell-glioma interaction enhances cell coat production by gliomas: novel suppressor mechanism. Science 220: 739-742, 1983
13. Figlin RA, Belldegrum A, Moldawer N et al.: Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2a: an active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 10(3): 414-421, 1992
14. Gately MK, Glaser M, Dick SJ et al.: In vitro studies on the cell-mediated immune response to human brain tumors: 1. Requirement for third-party stimulator lymphocytes in the induction of cell-mediated cytotoxic response to allogenic cultured gliomas. J Natl Cancer Inst 69: 1245-1254, 1982
15. Guinan EC, Gribben JG, Boussiotis VA et al.: Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 84: 3261-3282, 1994
16. Hayes RL, Koslow M, Hiesiger EM et al.: Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant gliomas. Cancer 76(5): 840-852, 1995
17. Holladay FP, Lopez G, De M, Morantz RA, Wood GW: Generation of cytotoxic immune responses against a rat glioma by in vivo priming and secondary in vitro stimulation with tumor cells. Neurosurg 30(4): 499-505, 1992
18. Jacobs SK, Wilson DJ, Kornblith PL et al.: Killing of human glioblastoma by interleukin-2 activated autologous lymphocytes. J Neurosurg 64: 114-117, 1986
19. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Apella E, Rosenberg SA.: Recognition of multiple epitopes in the human melanoma antigen gplOO by tumor infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154: 3961-3968, 1996
20. Kitahara T, Watanabe O, Yamaura A et al.: Establishment of interleukin-2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor. J Neuro-Oncol 4: 329-336, 1987
21. Kruse CA, Mitchell DH, Kleinschmidt-DeMasters et al.: Systematic chemotherapy combined with local adoptive immunotherapy cures rats with 9L gliosarcoma. J Neuro-Oncol 15:97-112, 1993
22. Kugel H, Heindel W, Ernestus RI, Bunke J, du Mesnil R, Friedman G: Human brain tumors: spectral patterns detected with localized H-I MR spectroscopy. Radiology 183: 701-709, 1992
23. La Salle GLG, Roberts JJ, Berrard S et al.: An adenovirus vector for gene therapy transfer into neurons and glia in the brain. Science 259: 988-1000, 1993
24. Mahaley MS Jr, Mettlin C, Natarajan N, Laws Jr, Peace BB: National survey on patterns of care for brain-tumor patients. J Neurosurg 71: 826-836, 1989
25. Merchant RE, Merchant LH, Cook SHS, McViciar DW, Young HF: Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (IL-2) for the treatment of patients with malignant brain tumor. Neurosurg 23: 725-731, 1988
26. Miescher S, Whiteside TL, de Tribolet N, von Fliedner V: In situ characterization, clonogenic potential and antitumor cytolytic activity of T-lymphocytes infiltrating human brain cancers. J Neurosurg 68: 438-448, 1988
27. Miyatake SI, Kikuchi H, Iwasaki K et al.: Specific cytotoxic activity of a T-lymphocyte clone derived from a patient with gliosarcoma. J Neurosurg 69: 751-759, 1988
28. Plautz GE, Barnette GH, Miller DW, Cohen BH, Prayson RA, Krauss JC, Luciono M, Kangisser DB, Shu S: Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg 89: 42-51, 1998
29. Quattrocchi KB, Miller CH, Wagner FC et al.: Cell-mediated immunity in several head injured patients: the role of suppressor lymphocytes and serum factors. J Neurosurg 77: 694-699, 1992
30. Quattrocchi KB, Lensley LL, Dull ST, Miller CH: Applicability of tumor-infiltrating lymphocytes in the treatment of malignant gliomas. American Association of Neurological Surgeons 1437 (Abstract): 280-281, 1995
31. Rosenberg SA: The adoptive immunotherapy of cancer using the transfer of activated lymphiod cells and interleukin-2. Semin Oncol 13: 200-206, 1986
32. Rosenberg SA, Packard BS, Aebersold PM et al.: Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. NEJM 319: 1676-1680, 1988
33. Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318-1321, 1986
34. Salcman M: Epidemiology and factors affecting survival. In: Apuzzo MLJ (ed) Malignant cerebral glioma. American Association of Neurological Surgeons, Park Ridge, IL, 1990, pp. 95-110
35. Saris SC, Spiess P, Lieberman DM et al.: Treatment of murine brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes. J Neurosurg 76: 513-519, 1992
36. Sawamura Y, Abe H, Aida T, Kobayashi H.: Isolation and in vitro growth of glioma infiltrating lymphocytes, and an analysis of their surface phenotypes. J Neurosurg 69: 745-750, 1988
37. Sawamura Y, Hosokawa M, Kupper MC et al.: Antitumor activity and surface phenotypes of human glioma-infiltrating lymphocytes after in vitro expansion in the presence of interleukin-2. Cane Res 49: 1843-1849, 1989
38. Shilyansky J, Nishimura MI, Yannelli JR et al.: T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor infiltrating lymphocyte lines. Proc Natl Acad Sci 91: 2829-2933, 1994
39. Smith MM, Thompson JE, Castillo M, Cush S, Mukherji SK, Miller CH, Quattrocchi KB: MR of recurrent high grade astrocytomas after intralesional immunotherapy. AJNR 17: 1065-1071, 1996
40. Yoshizawa H, Chang AE, Shu S: Specific adoptive immunotherapy mediated by tumor-draining lymph node cells subsequently activated with anti-CD3 and IL-2. J Immunol 147: 729-737, 1991